Vimarsana
Biggest News Aggregation in the World

Acorn Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acorn Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acorn Study Today - Breaking & Trending Today

BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting - Vimarsana News

BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting

Published: September 21, 2023

Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4 SAN RAFAEL, Calif., Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. , a global biotechnology...

Source: marketscreener.com
Related Topics:
United StatesAndrew VillaniTraci MccartyHank FuchsEarly Access ProgramWorldwide ResearchDrug AdministrationBiomarin Pharmaceutical IncEuropean Society For Paediatric EndocrinologyPrnewswire Biomarin Pharmaceutical IncEuropean CommissionCommittee For Medicinal Products Human UseEuropean Medicines AgencyExchange CommissionLabel Expansion Decisions ExpectedEuropean Regulatory AuthoritiesMarin PharmaceuticalAnnual European SocietyPaediatric EndocrinologyMedicinal ProductsHuman UseAction DateSupplemental New Drug ApplicationCentral European SummerGrowth Promoting Effects
Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting - Vimarsana News

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

Published: September 21, 2023

BioMarin Pharmaceutical Inc. announced that new data on VOXZOGO®? in children with achondroplasia will be presented at the 61st Annual European Society for Paediatric Endocrinology Meeting in The...

Source: marketscreener.com
Related Topics:
United StatesEuropean Medicines AgencyBiomarin Pharmaceutical IncEuropean Society For Paediatric EndocrinologyDrug AdministrationCommittee For Medicinal Products Human UseEarly Access ProgramBiomarin PharmaceuticalAnnual European SocietyPaediatric EndocrinologyMedicinal ProductsHuman UseAction DateSupplemental New Drug ApplicationOral PresentationsReal World SafetyCentral European Summer TimeGrowth Promoting EffectsChildren Aged OverCentral European SummerAcorn StudyAchondroplasia Patients Treated